Bluebird Historical Balance Sheet
BLUE Stock | USD 0.74 0.38 104.53% |
Trend analysis of Bluebird bio balance sheet accounts such as Other Current Liab of 8.6 M, Total Current Liabilities of 114.3 M or Total Stockholder Equity of 184.8 M provides information on Bluebird Bio's total assets, liabilities, and equity, which is the actual value of Bluebird bio to its prevalent stockholders. By breaking down trends over time using Bluebird Bio balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Bluebird bio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bluebird bio is a good buy for the upcoming year.
Bluebird Bio Inventory |
|
Bluebird |
About Bluebird Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Bluebird bio at a specified time, usually calculated after every quarter, six months, or one year. Bluebird Bio Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Bluebird Bio and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Bluebird currently owns. An asset can also be divided into two categories, current and non-current.
Bluebird Bio Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Bluebird Bio assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Bluebird bio books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Bluebird Bio balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bluebird bio are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Capital Stock
The total amount of a company's capital funded by shareholders through the issue and subscription of shares.Most accounts from Bluebird Bio's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Bluebird bio current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bluebird bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.At present, Bluebird Bio's Net Debt is projected to increase significantly based on the last few years of reporting. The current year's Cash is expected to grow to about 287 M, whereas Total Current Liabilities is forecasted to decline to about 114.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 78.5M | 52.0M | 9.0M | 8.6M | Total Assets | 593.8M | 554.9M | 619.2M | 1.1B |
Bluebird Bio balance sheet Correlations
Click cells to compare fundamentals
Bluebird Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bluebird Bio balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.7B | 1.8B | 593.8M | 554.9M | 619.2M | 1.1B | |
Other Current Liab | 141.6M | 180.1M | 78.5M | 52.0M | 9.0M | 8.6M | |
Total Current Liabilities | 223.6M | 203.6M | 153.0M | 128.2M | 200.1M | 114.3M | |
Total Stockholder Equity | 1.3B | 1.4B | 374.3M | 196.3M | 194.5M | 184.8M | |
Other Liab | 58.0M | 48.0M | 54.6M | 93K | 107.0K | 101.6K | |
Property Plant And Equipment Net | 337.1M | 346.9M | 101.2M | 291.4M | 267.0M | 174.1M | |
Current Deferred Revenue | 18.9M | 11.6M | 2.3M | 1.5M | 1.4M | 1.3M | |
Net Debt | (136.2M) | (124.7M) | (71.6M) | 168.4M | 193.6M | 203.3M | |
Retained Earnings | (2.3B) | (2.9B) | (3.7B) | (4.0B) | (4.3B) | (4.0B) | |
Accounts Payable | 43.0M | 13.8M | 25.9M | 14.9M | 18.5M | 15.1M | |
Cash | 327.2M | 317.7M | 161.2M | 113.0M | 221.8M | 287.0M | |
Non Current Assets Total | 575.3M | 565.7M | 257.3M | 355.4M | 337.5M | 352.4M | |
Non Currrent Assets Other | 79.2M | 72.8M | 53.3M | 52.1M | 54.3M | 35.0M | |
Other Assets | 79.2M | 72.8M | 53.3M | 52.1M | 59.9M | 33.2M | |
Cash And Short Term Investments | 1.2B | 1.3B | 396.6M | 181.7M | 209.0M | 198.6M | |
Common Stock Total Equity | 547K | 554K | 665K | 711K | 817.7K | 431.4K | |
Common Stock Shares Outstanding | 55.2M | 62.2M | 68.9M | 78.6M | 192.8M | 202.4M | |
Short Term Investments | 531.6M | 982.7M | 779.2M | 833.5M | 138.3M | 67.3M | |
Liabilities And Stockholders Equity | 1.7B | 1.8B | 593.8M | 554.9M | 638.1M | 1.1B | |
Non Current Liabilities Total | 218.9M | 222.6M | 66.5M | 230.3M | 224.5M | 161.3M | |
Other Current Assets | 45.7M | 522.2M | 25.6M | 8.6M | 9.9M | 9.4M | |
Other Stockholder Equity | 3.6B | 4.3B | 4.1B | 4.2B | 4.8B | 5.1B | |
Total Liab | 442.4M | 426.2M | 219.5M | 358.6M | 424.6M | 275.6M | |
Property Plant And Equipment Gross | 337.1M | 346.9M | 121.6M | 313.3M | 308.9M | 181.3M | |
Total Current Assets | 1.2B | 1.2B | 336.5M | 199.5M | 281.7M | 267.6M | |
Accumulated Other Comprehensive Income | (1.9M) | (5.5M) | (2.9M) | (4.1M) | (3.7M) | (3.8M) | |
Short Term Debt | 20.2M | 9.7M | 46.3M | 88.2M | 101.5M | 106.6M | |
Common Stock | 554K | 665K | 711K | 830K | 954.5K | 1.0M | |
Property Plant Equipment | 151.2M | 162.8M | 101.2M | 291.4M | 335.1M | 351.8M | |
Net Tangible Assets | 1.3B | 1.3B | 368.6M | 185.8M | 213.7M | 203.0M | |
Net Receivables | 12.8M | 2.4M | 11.4M | 10.8M | 22.2M | 23.3M | |
Retained Earnings Total Equity | (1.5B) | (2.3B) | (2.9B) | (3.7B) | (3.3B) | (3.2B) | |
Capital Surpluse | 3.4B | 3.6B | 4.3B | 4.1B | 4.7B | 2.6B | |
Inventory | (144.3M) | (149.7M) | (108.5M) | (1.4M) | 22.9M | 24.1M | |
Non Current Liabilities Other | 218.9M | 222.6M | 93K | 92K | 105.8K | 100.5K | |
Intangible Assets | 14.3M | 10.0M | 5.6M | 4.9M | 10.4M | 10.8M | |
Long Term Investments | 506.1M | 131.5M | 122.9M | 97.1M | 1.4M | 0.0 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bluebird bio is a strong investment it is important to analyze Bluebird Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bluebird Bio's future performance. For an informed investment choice regarding Bluebird Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bluebird bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.80) | Revenue Per Share 0.357 | Quarterly Revenue Growth 1.337 | Return On Assets (0.36) | Return On Equity (1.87) |
The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bluebird Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.